Genmab A/S/Genmab Finance LL
Genmab A/S is an international biotechnology enterprise headquartered in Copenhagen, Denmark, specializing in the research, development, and commercialization of innovative antibody-based therapeutics for cancer and other serious diseases. Utilizing proprietary technologies such as DuoBody and HexaBody, Genmab collaborates with global pharmaceutical partners to bring transformative medicine to patients. The company focuses on oncology, immunology, and rare disease research, maintaining a strong pipeline of clinical-stage products. Committed to pioneering therapeutic breakthroughs, Genmab operates R&D centers in Europe and North America and is listed on the Nasdaq Copenhagen and Nasdaq Global Select Market.
8 of the funds FundTelligence covers report a position in Genmab A/S/Genmab Finance LL.
- Legal name
- GENMAB A/S/GENMAB FINANCE LL
- Sector
- Health Care
- Country
- Denmark
- Funds holding it
- 8
Funds holding Genmab A/S/Genmab Finance LL
- Nordea US High Yield Sustainable Stars Bond Fund — Nordea Funds · 1.02 % (full portfolio disclosed, September 2026)
- Nordea US High Yield Bond — Nordea Funds · 0.67 % (full portfolio disclosed, September 2026)
- Nordea European High Yield Bond — Nordea Funds · 0.5 % (full portfolio disclosed, September 2026)
- Alfred Berg Global High Yield — Alfred Berg · 0.42 % (full portfolio disclosed, June 2026)
- Nordea International High Yield Opportunities — Nordea Funds · 0.36 % (full portfolio disclosed, September 2026)
- Templeton Global High Yield — Franklin Templeton · 0.31 % (full portfolio disclosed, September 2026)
- Nordea European High Yield Opportunities — Nordea Funds · 0.27 % (full portfolio disclosed, September 2026)
- Nordea Global High Yield Enhanced Bond Fund — Nordea Funds · 0.11 % (full portfolio disclosed, September 2026)